0
Clinical Investigations: ASTHMA |

Fluticasone Alone or in Combination With Salmeterol vs Triamcinolone in Asthma*

James Baraniuk, MD; John J. Murray, MD; Robert A. Nathan, MD, FCCP; William E. Berger, MD; Marty Johnson, MS; Lisa D. Edwards, PhD; Sharon Srebro, MD; Kathleen A. Rickard, MD
Author and Funding Information

*From the Georgetown University Medical Center (Dr. Baraniuk), Washington, DC; Allergy and Asthma Research Center (Dr. Murray), Vanderbilt Medical Center, Nashville, TN; Asthma and Allergy Associates, PC (Dr. Nathan), Pueblo, CO; Southern California Research Center (Dr. Berger), Mission Viejo, CA; and Glaxo Wellcome Inc (Mr. Johnson and Drs. Edwards, Srebro, and Rickard), Research Triangle Park, NC.

Correspondence to: James Baraniuk, MD, Georgetown University Medical Center, Division of Rheumatology, Immunology, and Allergy, GL-020 Gorman Building, 3800 Reservoir Rd, Washington, DC 20007-2197; e-mail: BARANIUJ@gunet.georgetown.edu



Chest. 1999;116(3):625-632. doi:10.1378/chest.116.3.625
Text Size: A A A
Published online

Objectives: To compare the efficacies of medium-dose fluticasone propionate (FP), medium-dose triamcinolone acetonide (TAA), and combined low-dose FP plus salmeterol (SL).

Design: Randomized, double-blind, triple-dummy, multicenter, 12-week clinical trial.

Setting: Allergy/respiratory care clinics.

Patients: Six hundred eighty patients with asthma previously uncontrolled with low-dose inhaled corticosteroids.

Interventions: FP, 220 μg bid; TAA, 600 μg bid; or FP, 88 μg plus SL, 42 μg bid.

Measurements and results: Outcome measures included FEV1, peak expiratory flow (PEF), supplemental albuterol use, nighttime awakenings, asthma symptoms, and physician global assessment. Compared with TAA, 600 μg bid, treatment with FP 220, μg bid, significantly increased FEV1, morning and evening PEF, and percent symptom-free days, and significantly reduced rescue albuterol use, number of nighttime awakenings, and overall asthma symptom scores (p ≤ 0.035). Improvements with low-dose FP, 88 μg, plus SL, 42μ g bid, were significantly (p ≤ 0.004) greater than TAA, 600 μg bid, in all the aforementioned efficacy measures as well as percent of rescue-free days. Combined low-dose FP, 88 μg, plus SL, 42 μg bid, also significantly increased FEV1 and percent of rescue-free days, and significantly reduced albuterol use compared with medium-dose FP, 220 μg bid (p ≤ 0.018). At endpoint, both FP, 220μ g bid, and FP, 88 μg, plus SL, 42 μg bid, significantly increased FEV1 by 0.48 L and 0.58 L, respectively, compared with 0.34 L with TAA, 600 μg bid.

Conclusion: In patients who are symptomatic while taking low-dose inhaled corticosteroids, medium-dose FP (440 μg/d) and combination treatment with low-dose FP (176 μg/d) plus SL (84 μg/d) are both more effective than medium-dose TAA (1200 μg/d) in improving pulmonary function and asthma symptom control.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543